-SEC Filing
BTIG Maintains Buy on Insulet, Lowers Price Target to $250
BTIG analyst Marie Thibault maintains Insulet (NASDAQ:PODD) with a Buy and lowers the price target from $310 to $250.
Related Posts
HUYA Misses Q1 Revenue Amid Live Streaming Crackdown, COVID Resurgence
HUYA Inc (NYSE:HUYA) reported a first-quarter FY22 revenue decline of 5.4% year-on-year to $388.8 million, missing the consensus of $435.6 million.…
Citigroup Downgrades Medtronic to Neutral, Lowers Price Target to $85
Citigroup analyst Joanne Wuensch downgrades Medtronic (NYSE:MDT) from Buy to Neutral and lowers the price target from $108 to $85.
BridgeBio Starts Dosing In Early-Stage Genetic Metabolism Disorder Trial
BridgeBio Pharma Inc (NASDAQ:BBIO) has dosed the first patient in its Phase 1 trial of BBP-671, an investigational oral therapy for…